Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

July 21, 2018

Chicago, Illinois

Continuing Education

Continuing Medical Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity enables a participant to earn up to 7.5 MOC points [and patient safety credit] towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.

Who Should Attend

This educational activity is specifically designed for gastroenterologists, hospitalists, internal medicine specialists, and other healthcare professionals (physicians-in-training, nurses, pharmacists, physicians assistants, etc.) involved and/or interested in the therapeutic management of patients with IBD.


After successful completion of this activity, participants should be able to:

  • Assess the mechanism of action and therapeutic potential of evolving treatments in IBD
  • Evaluate strategies for sequencing therapeutics in the era of biologics, immunotherapies and biosimilars
  • Identify a personalized therapeutic approach to optimally manage complex cases of CD
  • Interpret pivotal clinical trial data and novel management strategies for integration into clinical practice
  • Describe therapeutic strategies designed to prevent infections and extraintestinal manifestations in IBD
  • Define the role of treat-to-target in IBD regimens designed to maximize the opportunity to achieve remission and avoid relapse
  • Identify strategies to de-escalate therapy once remission is achieved in IBD
  • Assess the emerging role of biosimilars in IBD therapy, and their integration into current standards of care